Natural Product (NP) Details
General Information of the NP (ID: NP2169) | |||||
---|---|---|---|---|---|
Name |
Vitamin K
|
||||
Synonyms |
VITAMIN K; Kinadion; Konakion; Mephyton; Monodion; Kephton; Aqua mephyton; Synthex P; Mono-Kay; Combinal K1; Kativ N; K-Ject; 12001-79-5; Aquamephyton; Phythyl-menadion; 2',3'-trans-Vitamin K1; Aqua-Mephytin; Vitamin K1(20); .alpha.-Phylloquinone; trans-Phylloquinone; Phytomenadionum; 2-methyl-3-[(E)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione; 2-Methyl-3-phythyl-1,4-naphthochinon; 81818-54-4; Fitomenadione; 2-methyl-3-[(2E)-3,7,11,15-tetramethylhexadec-2-en-1-yl]-1,4-dihydronaphthalene-1,4-dione; 3-((2E)-3,7,11,15-tetramethylhexadec-2-enyl)-2-methylnaphthalene-1,4-dione; SMR000059144; Vitamin K semiquinone radical; a-Phylloquinone; NSC-270681; 2-methyl-3-[(2E)-3,7,11,15-tetramethylhexadec-2-en-1-yl]naphthalene-1,4-dione; NCGC00159423-02; Mephyton (TN); EINECS 234-408-7; EINECS 279-833-9; Vitamin K (generic); Phytomenadione (INN); Vitamin K1 (TN); 2-methyl-3-(3,7,11,15-tetramethylhexadec-2-en-1-yl)naphthalene-1,4-dione; Vitamin K1 (Phytonadione); Phytonadione (JP17/USP); MLS001332659; MLS001332660; CHEMBL520156; 2-Methyl-3-[(2E)-3,7,11,15-tetramethyl-2-hexadecenyl]naphthoquinone #; CHEBI:94399; [r-[r*,R*-(E)]]-2-Methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-napthalenedione; [r-[r*,R*-(E)]]-2-Methyl-3-(3-7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalenedione; HMS2232C17; 10485-69-5; BCP23822; BBL036678; NSC270681; STL559057; 2-Methyl-3-(3,7,11,15-tetramethylhexadec-2-enyl)-1,4-naphthoquinone; 2-Methyl-3-phytyl-1,4-napthoquinone; AKOS024284357; NCGC00186656-01; 27696-10-2; ST075162; VS-13623; P0642; C02059; D00148; 1, 2-methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-; 2-(3,7,11,15-Tetramethyl-2-hexadecenyl)-3-methyl-1,4-naphthoquinone; 2-(3,7,11,15-Tetramethylhexadec-2-enyl)-3-methylnaphthalene-1,4-dione; 2-Methyl-3-(3,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalenedione; (E)-2-Methyl-3-(3,7,11,15-tetramethylhexadec-2-en-1-yl)naphthalene-1,4-dione1; 1, 2-methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-, [R-[R*,R*-(E)]]-; 2-Methyl-3-[(2Z)-3,7,11,15-tetramethyl-2-hexadecenyl]-1,4-naphthoquinone; 1,4-Naphthalenedione, 2-methyl-3-((2E,7R,11R)-3,7,11,15-tetramethyl-2-hexadecenyl)-, radical ion(1-); 1,4-Naphthalenedione, 2-methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-, radical ion(1-), (R-(R*,R*-(E)))-; 2581046-19-5
Click to Show/Hide
|
||||
Species Origin | Medicago sativa ... | Click to Show/Hide | |||
Medicago sativa | |||||
Disease | Breast cancer [ICD-11: 2C60] | Investigative | [1] | ||
Structure |
![]() |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C31H46O2
|
||||
PubChem CID | |||||
Canonical SMILES |
CC1=C(C(=O)C2=CC=CC=C2C1=O)CC=C(C)CCCC(C)CCCC(C)CCCC(C)C
|
||||
InChI |
1S/C31H46O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,18-20,22-24H,9-17,21H2,1-6H3/b25-20+
|
||||
InChIKey |
MBWXNTAXLNYFJB-LKUDQCMESA-N
|
||||
CAS Number |
CAS 12001-79-5
|
||||
ChEBI ID | |||||
Herb ID | |||||
SymMap ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Sorafenib | Renal cell carcinoma | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Up-regulation | Expression | CDH1 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | HGFAC | Molecule Info | |||
Up-regulation | Expression | MET | Molecule Info |
Pathway MAP
|
||
In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
Experimental
Result(s) |
Sorafenib and vitamin K can function synergistically to inhibit the migration and proliferation of HCC cells. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Coagulation factor IIa (F2) | Molecule Info | [3] | |
KEGG Pathway | Neuroactive ligand-receptor interaction | Click to Show/Hide | ||
2 | Complement and coagulation cascades | |||
3 | Regulation of actin cytoskeleton | |||
NetPath Pathway | TCR Signaling Pathway | Click to Show/Hide | ||
Panther Pathway | Blood coagulation | Click to Show/Hide | ||
Pathwhiz Pathway | Vitamin K Metabolism | Click to Show/Hide | ||
2 | Coagulation | |||
Pathway Interaction Database | Thrombin/protease-activated receptor (PAR) pathway | Click to Show/Hide | ||
2 | Angiopoietin receptor Tie2-mediated signaling | |||
3 | FOXA2 and FOXA3 transcription factor networks | |||
4 | PAR4-mediated thrombin signaling events | |||
5 | Syndecan-4-mediated signaling events | |||
6 | PAR1-mediated thrombin signaling events | |||
Reactome | Intrinsic Pathway of Fibrin Clot Formation | Click to Show/Hide | ||
2 | Common Pathway of Fibrin Clot Formation | |||
3 | Gamma-carboxylation of protein precursors | |||
4 | Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus | |||
5 | Removal of aminoterminal propeptides from gamma-carboxylated proteins | |||
6 | Cell surface interactions at the vascular wall | |||
7 | Peptide ligand-binding receptors | |||
8 | Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | |||
9 | G alpha (q) signalling events | |||
10 | Thrombin signalling through proteinase activated receptors (PARs) | |||
WikiPathways | Complement and Coagulation Cascades | Click to Show/Hide | ||
2 | Regulation of Actin Cytoskeleton | |||
3 | IL1 and megakaryotyces in obesity | |||
4 | Regulation of Insulin-like Growth Factor (IGF) Transport and Uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | |||
5 | PTM: gamma carboxylation, hypusine formation and arylsulfatase activation | |||
6 | Blood Clotting Cascade | |||
7 | Gastrin-CREB signalling pathway via PKC and MAPK | |||
8 | Thrombin signalling through proteinase activated receptors (PARs) | |||
9 | Platelet Aggregation (Plug Formation) | |||
10 | GPCR ligand binding | |||
11 | GPCR downstream signaling | |||
12 | Formation of Fibrin Clot (Clotting Cascade) | |||
13 | Cell surface interactions at the vascular wall | |||
14 | Folate Metabolism | |||
15 | Vitamin B12 Metabolism | |||
16 | Selenium Micronutrient Network |



